Published in J Antimicrob Chemother on November 20, 2012
Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med (2014) 11.87
Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature (2012) 4.37
Randomized controlled trial of a traditional preparation of Artemisia annua L. (Annual Wormwood) in the treatment of malaria. Trans R Soc Trop Med Hyg (2004) 3.52
Short report: Piloting paperless data entry for clinical research in Africa. Am J Trop Med Hyg (2005) 2.85
Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. PLoS One (2009) 2.43
In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. Antimicrob Agents Chemother (2009) 2.36
Fosmidomycin for malaria. Lancet (2002) 2.03
Declining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast. PLoS One (2011) 2.00
Chloroquine resistance before and after its withdrawal in Kenya. Malar J (2009) 1.88
Long-term treatment of intestinal helminths increases mite skin-test reactivity in Gabonese schoolchildren. J Infect Dis (2004) 1.85
Short report: association between chloroquine and amodiaquine resistance and allelic variation in the Plasmodium falciparum multiple drug resistance 1 gene and the chloroquine resistance transporter gene in isolates from the upper Nile in southern Sudan. Am J Trop Med Hyg (2003) 1.72
Vaccine-like immunity against malaria by repeated causal-prophylactic treatment of liver-stage Plasmodium parasites. J Infect Dis (2009) 1.70
Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria. Expert Opin Pharmacother (2007) 1.64
Assessment of volume depletion in children with malaria. PLoS Med (2004) 1.51
Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg (2014) 1.51
Population pharmacokinetics of artesunate and dihydroartemisinin following intra-rectal dosing of artesunate in malaria patients. PLoS Med (2006) 1.42
Fosmidomycin for the treatment of malaria. Parasitol Res (2002) 1.40
Characteristics of Plasmodium falciparum dhfr haplotypes that confer pyrimethamine resistance, Kilifi, Kenya, 1987--2006. J Infect Dis (2008) 1.32
Natural immunization against malaria: causal prophylaxis with antibiotics. Sci Transl Med (2010) 1.31
Defining clinical malaria: the specificity and incidence of endpoints from active and passive surveillance of children in rural Kenya. PLoS One (2010) 1.30
Diarrhoea complicating severe acute malnutrition in Kenyan children: a prospective descriptive study of risk factors and outcome. PLoS One (2012) 1.26
Why has the dihydrofolate reductase 164 mutation not consistently been found in Africa yet? Trans R Soc Trop Med Hyg (2005) 1.24
Optimal sampling designs for estimation of Plasmodium falciparum clearance rates in patients treated with artemisinin derivatives. Malar J (2013) 1.21
Artesunate-clindamycin versus quinine-clindamycin in the treatment of Plasmodium falciparum malaria: a randomized controlled trial. Clin Infect Dis (2005) 1.18
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya. Antimicrob Agents Chemother (2010) 1.15
Clinical and parasitological characteristics of puerperal malaria. J Infect Dis (2005) 1.15
Population genetic analysis of Plasmodium falciparum parasites using a customized Illumina GoldenGate genotyping assay. PLoS One (2011) 1.13
New cercopithecoids and a hominoid from 12.5 Ma in the Tugen Hills succession, Kenya. J Hum Evol (2002) 1.13
Factors associated with herpes simplex virus type 2 incidence in a cohort of human immunodeficiency virus type 1-seronegative Kenyan men and women reporting high-risk sexual behavior. Sex Transm Dis (2011) 1.12
Antibody responses to Plasmodium falciparum merozoite surface protein-1 and efficacy of amodiaquine in Gabonese children with P. falciparum malaria. J Infect Dis (2003) 1.11
In vivo and in vitro efficacy of amodiaquine against Plasmodium falciparum in an area of continued use of 4-aminoquinolines in East Africa. J Infect Dis (2009) 1.08
Genome-wide screen identifies new candidate genes associated with artemisinin susceptibility in Plasmodium falciparum in Kenya. Sci Rep (2013) 1.07
In vitro selection of Plasmodium falciparum drug-resistant parasite lines. J Antimicrob Chemother (2009) 1.07
Cardiac function and hemodynamics in Kenyan children with severe malaria. Crit Care Med (2010) 1.05
NF135.C10: a new Plasmodium falciparum clone for controlled human malaria infections. J Infect Dis (2012) 1.04
In vitro activity of antifolate and polymorphism in dihydrofolate reductase of Plasmodium falciparum isolates from the Kenyan coast: emergence of parasites with Ile-164-Leu mutation. Antimicrob Agents Chemother (2009) 1.04
Effect of folate derivatives on the activity of antifolate drugs used against malaria and cancer. Parasitol Res (2008) 1.00
The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data. BMC Med (2015) 0.99
Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother (2011) 0.98
Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone. Br J Clin Pharmacol (2006) 0.98
Update on genetic markers of quinine resistance in Plasmodium falciparum. Mol Biochem Parasitol (2011) 0.97
PlasmoView: a web-based resource to visualise global Plasmodium falciparum genomic variation. J Infect Dis (2013) 0.97
Antimalarial chemotherapy: young guns or back to the future? Trends Parasitol (2003) 0.95
Grinding surface roughness measurement based on the co-occurrence matrix of speckle pattern texture. Appl Opt (2006) 0.95
Update on the in vivo tolerance and in vitro reduced susceptibility to the antimalarial lumefantrine. J Antimicrob Chemother (2012) 0.94
Chemosensitization of Plasmodium falciparum by probenecid in vitro. Antimicrob Agents Chemother (2003) 0.94
Delayed parasite elimination in human infections treated with clindamycin parallels 'delayed death' of Plasmodium falciparum in vitro. Int J Parasitol (2006) 0.93
Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis. Malar J (2015) 0.91
Baseline in vitro activities of the antimalarials pyronaridine and methylene blue against Plasmodium falciparum isolates from Kenya. Antimicrob Agents Chemother (2011) 0.90
Methotrexate is highly potent against pyrimethamine-resistant Plasmodium vivax. J Infect Dis (2010) 0.90
Repeat polymorphisms in the low-complexity regions of Plasmodium falciparum ABC transporters and associations with in vitro antimalarial responses. Antimicrob Agents Chemother (2013) 0.88
Immune responses induced by repeated treatment do not result in protective immunity to Schistosoma haematobium: interleukin (IL)-5 and IL-10 responses. J Infect Dis (2002) 0.87
Lack of avidity maturation of merozoite antigen-specific antibodies with increasing exposure to Plasmodium falciparum amongst children and adults exposed to endemic malaria in Kenya. PLoS One (2012) 0.85
Genome wide adaptations of Plasmodium falciparum in response to lumefantrine selective drug pressure. PLoS One (2012) 0.85
Arrested Plasmodium liver stages as experimental anti-malaria vaccines. Hum Vaccin (2011) 0.85
In vitro activities of 2,4-diaminoquinazoline and 2,4-diaminopteridine derivatives against Plasmodium falciparum. Antimicrob Agents Chemother (2004) 0.84
2,4-diaminopteridine-based compounds as precursors for de novo synthesis of antifolates: a novel class of antimalarials. Antimicrob Agents Chemother (2005) 0.82
Age-dependent enhancement of IFN-gamma responses to Plasmodium falciparum liver stage antigen-1 T cell epitopes. Parasitol Res (2002) 0.82
Molecular monitoring of the Leu-164 mutation of dihydrofolate reductase in a highly sulfadoxine/pyrimethamine-resistant area in Africa. Malar J (2003) 0.82
Characterisation of the bifunctional dihydrofolate synthase-folylpolyglutamate synthase from Plasmodium falciparum; a potential novel target for antimalarial antifolate inhibition. Mol Biochem Parasitol (2010) 0.82
Nitric oxide generation in children with malaria and the NOS2G-954C promoter polymorphism. Am J Physiol Regul Integr Comp Physiol (2010) 0.81
The molecular basis of folate salvage in Plasmodium falciparum: characterization of two folate transporters. J Biol Chem (2011) 0.81
Dental remains of Equatorius africanus from Kipsaramon, Tugen Hills, Baringo District, Kenya. J Hum Evol (2002) 0.81
A phase I trial to evaluate the safety and pharmacokinetics of low-dose methotrexate as an anti-malarial drug in Kenyan adult healthy volunteers. Malar J (2011) 0.81
Preliminary description of the Equatorius africanus partial skeleton (KNM-TH 28860) from Kipsaramon, Tugen Hills, Baringo District, Kenya. J Hum Evol (2002) 0.80